CoChat

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Dimopoulos, Meletios A., Richardson, Paul G., Brandenburg, Nancy, Yu, Zhinuan, Weber, Donna M., Niesvizky, Ruben, Morgan, Gareth J. · 2012 · Blood
Cited by 148

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62. IR of invasive (hematologic and solid tumor) SPMs was 2.08, consistent with the background incidence of developing cancer. In a separate analysis of pooled data from pivotal phase 3 trials of relapsed or refractory MM (N = 703), the overall IR of SPMs was 3.98 (95% confidence interval [CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI, 0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66), respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and 0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken into account before initiating lenalidomide treatment. In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-08-373514

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 148

Metadata

Authors
Dimopoulos, M. A., Richardson, P. G., Brandenburg, N., Yu, Z., Weber, D. M., Niesvizky, R., & Morgan, G. J.
Venue
Blood
Published
2012-03-22
Volume
119
Issue
12
Pages
2764-2767
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2080030013
Cited by
148
References
4
FWCI
16.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. https://app.cochat.ai/papers/10.1182/blood-2011-08-373514
The paper
Dimopoulos, M. A., Richardson, P. G., Brandenburg, N., Yu, Z., Weber, D. M., Niesvizky, R., & Morgan, G. J. (2012). A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. https://doi.org/10.1182/blood-2011-08-373514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.